450 results on '"Peipp, Matthias"'
Search Results
2. Prosaposin hyperglycosylation: a novel tumor immune escape mechanism and implications for cancer immunotherapy
3. Targeted siRNA nanocarrier: a platform technology for cancer treatment
4. Rekrutierung von Natürlichen Killerzellen durch optimierte Immunliganden
5. CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies
6. Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis
7. Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL
8. Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia
9. Combining Cellular Immunization and Phage Display Screening Results in Novel, FcγRI-Specific Antibodies
10. The selection of variable regions affects effector mechanisms of IgA antibodies against CD20
11. Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies
12. Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
13. Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade
14. Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3
15. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells
16. Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition
17. Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma
18. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
19. An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts
20. Abstract 2954: MAIT engagers: An efficacious novel modality in the field of T-cell engagers for the treatment of solid tumors
21. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
22. Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma
23. Novel NKG2D-directed bispecific antibodies enhance antibodymediated killing of malignant B cells by NK cells and T cells.
24. NKp46 ‐specific single domain antibodies enable facile engineering of various potent NK cell engager formats
25. Editorial: Effector functions of therapeutic antibodies
26. NKp46‐specific single domain antibodies enable facile engineering of various potent NK cell engager formats
27. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages
28. Dual intracellular targeting by ruxolitinib and the Mcl-1 inhibitor S63845 in interleukin-6-dependent myeloma cells blocks in vivo tumor growth
29. Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody
30. Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab
31. The relevance of complement in pemphigoid diseases: A critical appraisal
32. Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia
33. Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display
34. Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab
35. Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen
36. Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer
37. The Antibody Zalutumumab Inhibits Epidermal Growth Factor Receptor Signaling by Limiting Intra- and Intermolecular Flexibility
38. Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors
39. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
40. Blocking the Don't Eat Me Signal (CD47-SIRPα Axis) to Improve Antibody-Based Immunotherapy of Multiple Myeloma
41. An Inducible Leukemia-Associated Transcription Factor Facilitates Large-Scale Ex Vivo Generation of Functional Human Macrophages
42. IMMU-39. EVALUATION OF CD317-TARGETING CAR T CELLS AS A NOVEL IMMUNOTHERAPEUTIC STRATEGY AGAINST GLIOBLASTOMA
43. The novel dual topoisomerase inhibitor P8-D6 shows anti-myeloma activity in vitro and in vivo
44. ADAM17-overexpressing breast cancer cells selectively targeted by antibody–toxin conjugates
45. Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma
46. Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions
47. Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo
48. New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
49. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength
50. The selection of variable regions affects effector mechanisms of IgA antibodies against CD20
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.